CME in Minutes: Education in Primary Care

Please visit answersincme.com/860/103760795-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Keith C. Ferdinand, MD; Mike Sharma, MD, MSc; and Eddie Needham, MD, FAAFP. In this activity, experts in atrial fibrillation (AF) discuss evidence-based strategies to optimize stroke prevention, address anticoagulation gaps in clinical practice, and prepare for emerging approaches to anticoagulation. Upon completion of this activity, participants should be better able to: Apply evidence-based risk stratification tools and guidelines to address anticoagulation gaps in primary care patients with AF; Assess the clinical impact of suboptimal anticoagulation on AF stroke prevention; Evaluate emerging strategies for AF stroke prevention, including factor XI/XIa inhibitors; and Outline multidisciplinary, equity-focused care strategies incorporating social determinants to optimize AF stroke prevention in diverse populations.

Please visit answersincme.com/XUG860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Sara A. Hurvitz, MD, FACP. In this activity, an expert in breast cancer discusses the evidence for TROP2-directed antibody-drug conjugates in metastatic triple-negative disease (mTNBC). Upon completion of this activity, participants should be better able to: Review the clinical impact of TROP2-directed antibody-drug conjugates (ADCs) for the management of mTNBC; Evaluate the clinical implications of the evidence exploring first-line use of TROP2 ADCs in combination with immunotherapy for mTNBC; and Develop an evidence-informed strategy that incorporates TROP2-directed ADCs and immunotherapy combinations into first-line management of mTNBC, where appropriate.

Please visit answersincme.com/GFY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Vishal A. Patel, MD; and Jonathan S. Zager, MD, FACS, FSSO. In this activity, experts in cutaneous oncology discuss the evolving role of gene expression profiling (GEP) tests in refining risk assessment and supporting individualized, multidisciplinary management strategies for patients with melanoma. Upon completion of this activity, participants should be better able to: Identify the clinical rationale for using GEP tests to stratify the risk of disease progression in patients with cutaneous melanoma; Review the clinical evidence, including guideline-supported data, for GEP tests to stratify disease progression risk in patients with cutaneous melanoma; Formulate multidisciplinary strategies for incorporating the results of GEP tests into risk-based management of patients with cutaneous melanoma; and Outline patient-centered approaches to integrating GEP tests into the management of patients with cutaneous melanoma at risk of metastasis.

Please visit answersincme.com/2026-MC-001884-replay860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Marc Serota, MD; Kristin Sokol, MD, MS, MPH; and Michelle Tarbox, MD. In this activity, experts in chronic spontaneous urticaria (CSU) discuss strategies to reduce diagnostic delays and how to personalize care beyond antihistamines. Upon completion of this activity, participants should be better able to: Recognize the impact of delayed diagnosis on disease control in patients with CSU; Review key inflammatory pathways—including type 2 inflammation—in CSU pathogenesis and how targeted therapies modulate them; Assess the latest clinical data for targeted therapies for the treatment of CSU; and Apply evidence-based strategies to personalize the management of antihistamine-refractory CSU.

Please visit answersincme.com/860/101834101-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Simpa S. Salami, MD, MPH; and Neal D. Shore, MD, FACS. In this activity, experts in prostate cancer discuss new evidence for individualized, evidence-based treatment strategies in metastatic hormone-sensitive disease. Upon completion of this activity, participants should be better able to: Evaluate the clinical implications of the most recent data informing the standard of care treatment options for mHSPC; Integrate patient-, disease-, and therapy-related factors to develop individualized, evidence-based treatment strategies for mHSPC; and Design patient-centered care approaches that balance the benefit and risk of treatment to optimize outcomes in mHSPC.